Who
Francois Nader
Director
Company insider
Files Form 4 as: Director, Moderna; Director, Tectonic Therapeutic; Director, Talaris Therapeutics; Director, Acceleron Pharma; Director, Alexion Pharmaceuticals; Director, Prevail Therapeutics; Director, Baxalta; Director, Trevena.
In numbers
- Trades disclosed
- 263
- Buys
- 7
- Sells
- 7
- Bought
- $1.2M
- Sold
- $11.9M
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 5 Jun 2006
- Last trade
- 6 May 2026
- Last filed
- 8 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,454 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,185 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,454 at $0.00 | filing |
| 6 May 2026filed 8 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,185 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —12,174 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,174 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,174 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —12,174 | filing |
| 1 Apr 2026filed 3 Apr 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,400 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,378 at $0.00 | filing |
| 30 Apr 2025filed 1 May 2025 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,174 at $0.00 | filing |
| 6 May 2024filed 7 May 2024 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,557 at $0.00 | filing |
| 13 Jun 2023filed 14 Jun 2023 | Talaris Therapeuticsoption or derivative | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 3 May 2023filed 5 May 2023 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,134 at $0.00 | filing |
| 25 Jul 2022filed 13 Sep 2022 | Talaris Therapeutics | SEC FORM 4 Code J | —138,500 at $0.00 | filing |
| 25 Jul 2022filed 13 Sep 2022 | Talaris Therapeutics | SEC FORM 4 Code J | —138,500 at $0.00 | filing |
| 25 Jul 2022filed 25 Jul 2022 | Talaris Therapeutics | SEC FORM 4 Code J | —138,500 at $0.00 | filing |
| 25 Jul 2022filed 25 Jul 2022 | Talaris Therapeutics | SEC FORM 4 Code J | —138,500 at $0.00 | filing |
| 21 Jul 2022filed 13 Sep 2022 | Talaris Therapeutics | SEC FORM 4 Code J | —248,432 at $0.00 | filing |
News
Moderna (NASDAQ:MRNA) Shares Up 1.2% – Here's WhyMRNA · dailypolitical.com · 13 Oct 2026Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?MRNA · insidermonkey.com · 9 Oct 2026
0 headlines in the last 90 days name Francois Nader; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.